Antibiotic Pricing Model Reform Offered As Solution To Combat Resistance
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry declaration calls for government funding for drug development and pricing that takes into account antibiotic's benefits.
You may also be interested in...
Pharma's Latest Davos Pledge: Sincere, Or Just Keeping Up Appearances?
Many hope the "dialogue of the deaf" between pharma and other healthcare stakeholders can be truly bridged by the industry's latest Davos declaration to collaborate in targeting chronic diseases of the poor.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.